Ozlo's $22 million raise bets sleep earbuds can also treat tinnitus.

A familiar pitch gets a new number attached

Ozlo, the Boston company behind the Sleepbuds earbuds, announced a $22 million Series B on October 29, 2026, led by Modi Ventures. The round also drew LifeArc, Artis Ventures, Resmed, Scrum Ventures, Drive by DraftKings and several other existing backers, plus a handful of named individual investors including NFL veteran Nick Foles and Whole30 founder Melissa Urban. CEO N.B. Patil called the moment one where Ozlo Sleepbuds helped define a new category of technology designed specifically for sleep, and Modi Ventures founder Sahir Ali said Ozlo has nailed that fundamental requirement.

That's the easy part to verify. Ozlo is a real, 60-person company founded by former Bose engineers, and TechCrunch covered it independently back in January 2026, when CEO Patil told the outlet the company was already in the process of closing this same Series B. The headline number lines up with a round that took most of a year to close, which is normal. What's worth reading past the press release for is what the money is actually funding, and whether the company's newest health claim, that its earbuds can help tinnitus, holds up.

What $22 million actually buys, and what it doesn't

Ozlo's own announcement says the total "includes previously issued convertible instruments." In plain terms, some of that $22 million isn't fresh cash raised this week, it's debt that had already come in and is now converting into equity alongside the new money. That's a common and legitimate way to structure a round, but it means the headline figure overstates how much new capital just landed in Ozlo's account. The company says it will spend the proceeds on scaling Sleepbuds sales internationally, building next-generation hardware, and pushing a tinnitus product toward the FDA.

Ozlo says it has sold Sleepbuds to more than 260,000 customers in under two years, which is a meaningful number for a hardware startup at this stage, though it's a company-reported figure rather than an independently audited one.

The tinnitus claim, and what's actually behind it

Here's the part that deserves more scrutiny than a funding wire gets by default. Ozlo says about 15% of its customers report tinnitus, the persistent ringing or buzzing that has no outside source, and the company has told TechCrunch that a study conducted with Walter Reed suggested overnight masking at specific frequencies may help. That study hasn't been published or peer reviewed, as far as we could confirm. Ozlo's actual tinnitus product is still working through the regulatory steps needed for FDA review. It is not cleared or approved today.

Independent reviewers, including a hearing clinic that tested the current Sleepbuds specifically for tinnitus relief, describe real but modest and inconsistent benefit: masking sounds that help on some nights and not others, with no controlled study behind the experience. That's a reasonable outcome for a comfort product. It's a much weaker foundation for marketing language that edges toward a medical claim, which is exactly why the FDA review step matters before anyone should expect more than noise masking from these earbuds.

Sleep data, not earbuds, is the real business

Patil has been fairly direct about where Ozlo is actually headed: the Sleepbuds are the entry point for a sleep-data platform. The earbuds carry light, noise and motion sensors, and Ozlo already has a content partnership with Calm and a referral relationship with Dreem Health, a virtual sleep clinic, to route users who need more than white noise toward an actual clinician. The company has also acquired Segotia, an Irish EEG neurotech firm, with an EEG-enabled product reportedly planned for 2027, which would push Ozlo further toward being a medical device company rather than a gadget maker.

That's a more ambitious and more scrutinized path than selling earbuds. If you're weighing whether a wearable's health claims are worth the premium, it's worth the same questions we asked when Oura's IPO filing put a number on smart-ring data, or when we checked how reliable smart rings actually are for sleep tracking: does the device clear a regulatory bar, or is it still selling you on a study that hasn't been published yet.

Our take

The $22 million is real, the investors are real, and Ozlo has a genuine, growing customer base. None of that means its tinnitus claim is proven. Buy Sleepbuds if you want a comfortable way to mask a noisy bedroom, that part of the pitch holds up fine on its own. Don't buy them expecting a treatment for tinnitus until the company publishes real data and the FDA has actually looked at it.

Health Trend Wire holds no position in Ozlo and was not paid for this article. This is general information, not medical or financial advice.